Premium
RET ‐rearranged non‐small‐cell lung cancer and therapeutic implications
Author(s) -
Loh Zoe,
Mitchell Paul,
John Thomas,
Arulananda Surein
Publication year - 2019
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.14654
Subject(s) - anaplastic lymphoma kinase , medicine , cancer research , lung cancer , epidermal growth factor receptor , tyrosine kinase , targeted therapy , mutation , oncogene , population , oncology , cancer , precision medicine , receptor tyrosine kinase , gene , pathology , receptor , cell cycle , genetics , biology , environmental health , malignant pleural effusion
First‐line tyrosine kinase inhibitors are standard of care for non‐small‐cell lung cancers (NSCLC) harbouring an epidermal growth factor receptor mutation, anaplastic lymphoma kinase fusion or c‐ros oncogene 1 rearrangement. Other targetable oncogenic drivers have been identified but testing for these is neither funded nor commonly performed in Australia. Using a case example, we discuss the importance of considering several other genomic aberrations in our population, such as rearrangements in the RET proto‐oncogene, which occur in 1–2% of lung adenocarcinoma. New oncogenic drivers and corresponding targeted agents are constantly being discovered; these will continue to refine the treatment of non‐small‐cell lung cancer in the era of precision medicine.